SCHEMBL23988269

SCHEMBL23988269

CCOc1c(C)cnc(CC(O)c2nc3cc(-n4cccc4)ccc3[nH]2)c1C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.36
HTT P42858 2/20 0.36
MEN1 O00255 1/20 0.36
WDR5 P61964 3/20 0.33
SARM1 Q6SZW1 1/20 0.33
BRS3 P32247 2/20 0.31
HSP90AA1 P07900 1/20 0.31
HSP90AB1 P08238 1/20 0.31
CYP2C9 P11712 2/20 0.30
ALDH1A1 P00352 2/20 0.30
KDM4E B2RXH2 1/20 0.30
DDAH1 O94760 1/20 0.30
ABCB11 O95342 1/20 0.30
ATP1A1 P05023 1/20 0.30
ATP1B1 P05026 1/20 0.30
CYP1A2 P05177 1/20 0.30
CHRM2 P08172 1/20 0.30
ABCB1 P08183 1/20 0.30
CYP3A4 P08684 1/20 0.30
ADORA3 P0DMS8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23988504 0.92 KMT2A (0.41) KMT2AHTTMEN1WDR5SARM1
SCHEMBL23988270 0.90 SARM1 (0.45) KMT2AWDR5SARM1CYP2C9ALDH1A1
SCHEMBL24571947 0.84 KMT2A (0.37) KMT2AHTTMEN1WDR5SARM1
SCHEMBL23988579 0.83 BRS3 (0.45) KMT2AHTTMEN1WDR5SARM1
SCHEMBL23988583 0.80 KMT2A (0.35) KMT2AHTTWDR5SARM1BRS3
SCHEMBL24571950 0.80 KMT2A (0.41) KMT2AHTTMEN1WDR5SARM1
SCHEMBL23988355 0.80 ATP4A (0.38) KMT2AHTTMEN1WDR5SARM1
SCHEMBL23988470 0.78 WDR5 (0.33) KMT2AHTTWDR5SARM1BRS3
SCHEMBL23988577 0.76 BRS3 (0.52) KMT2AHTTMEN1WDR5SARM1
SCHEMBL23988273 0.74 KMT2A (0.58) KMT2AHTTMEN1WDR5SARM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210338650-A1 CXCL10 Inhibitors AFECTA PHARMACEUTICALS, INC. (US) 2021-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210338650-A1 CXCL10 Inhibitors CXCL10, CCL5, CCL11 KMT2A 3380/4885HTT 3627/4885MEN1 3946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.